Cargando…

Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) is characterized by an extremely poor prognosis. An inflammatory microenvironment triggers the pronounced desmoplasia, the selection of cancer stem-like cells (CSCs) and therapy resistance. The anti-inflammatory drug aspirin is suggested to lower the risk for P...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiyao, Liu, Li, Fan, Pei, Bauer, Nathalie, Gladkich, Jury, Ryschich, Eduard, Bazhin, Alexandr V., Giese, Nathalia A., Strobel, Oliver, Hackert, Thilo, Hinz, Ulf, Gross, Wolfgang, Fortunato, Franco, Herr, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496413/
https://www.ncbi.nlm.nih.gov/pubmed/25846752
_version_ 1782380399010250752
author Zhang, Yiyao
Liu, Li
Fan, Pei
Bauer, Nathalie
Gladkich, Jury
Ryschich, Eduard
Bazhin, Alexandr V.
Giese, Nathalia A.
Strobel, Oliver
Hackert, Thilo
Hinz, Ulf
Gross, Wolfgang
Fortunato, Franco
Herr, Ingrid
author_facet Zhang, Yiyao
Liu, Li
Fan, Pei
Bauer, Nathalie
Gladkich, Jury
Ryschich, Eduard
Bazhin, Alexandr V.
Giese, Nathalia A.
Strobel, Oliver
Hackert, Thilo
Hinz, Ulf
Gross, Wolfgang
Fortunato, Franco
Herr, Ingrid
author_sort Zhang, Yiyao
collection PubMed
description Pancreatic ductal adenocarcinoma (PDA) is characterized by an extremely poor prognosis. An inflammatory microenvironment triggers the pronounced desmoplasia, the selection of cancer stem-like cells (CSCs) and therapy resistance. The anti-inflammatory drug aspirin is suggested to lower the risk for PDA and to improve the treatment, although available results are conflicting and the effect of aspirin to CSC characteristics and desmoplasia in PDA has not yet been investigated. We characterized the influence of aspirin on CSC features, stromal reactions and gemcitabine resistance. Four established and 3 primary PDA cell lines, non-malignant cells, 3 patient tumor-derived CSC-enriched spheroidal cultures and tissues from patients who did or did not receive aspirin before surgery were analyzed using MTT assays, flow cytometry, colony and spheroid formation assays, Western blot analysis, antibody protein arrays, electrophoretic mobility shift assays (EMSAs), immunohistochemistry and in vivo xenotransplantation. Aspirin significantly induced apoptosis and reduced the viability, self-renewal potential, and expression of proteins involved in inflammation and stem cell signaling. Aspirin also reduced the growth and invasion of tumors in vivo, and it significantly prolonged the survival of mice with orthotopic pancreatic xenografts in combination with gemcitabine. This was associated with a decreased expression of markers for progression, inflammation and desmoplasia. These findings were confirmed in tissue samples obtained from patients who had or had not taken aspirin before surgery. Importantly, aspirin sensitized cells that were resistant to gemcitabine and thereby enhanced the therapeutic efficacy. Aspirin showed no obvious toxic effects on normal cells, chick embryos or mice. These results highlight aspirin as an effective, inexpensive and well-tolerated co-treatment to target inflammation, desmoplasia and CSC features PDA.
format Online
Article
Text
id pubmed-4496413
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44964132015-07-15 Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer Zhang, Yiyao Liu, Li Fan, Pei Bauer, Nathalie Gladkich, Jury Ryschich, Eduard Bazhin, Alexandr V. Giese, Nathalia A. Strobel, Oliver Hackert, Thilo Hinz, Ulf Gross, Wolfgang Fortunato, Franco Herr, Ingrid Oncotarget Research Paper Pancreatic ductal adenocarcinoma (PDA) is characterized by an extremely poor prognosis. An inflammatory microenvironment triggers the pronounced desmoplasia, the selection of cancer stem-like cells (CSCs) and therapy resistance. The anti-inflammatory drug aspirin is suggested to lower the risk for PDA and to improve the treatment, although available results are conflicting and the effect of aspirin to CSC characteristics and desmoplasia in PDA has not yet been investigated. We characterized the influence of aspirin on CSC features, stromal reactions and gemcitabine resistance. Four established and 3 primary PDA cell lines, non-malignant cells, 3 patient tumor-derived CSC-enriched spheroidal cultures and tissues from patients who did or did not receive aspirin before surgery were analyzed using MTT assays, flow cytometry, colony and spheroid formation assays, Western blot analysis, antibody protein arrays, electrophoretic mobility shift assays (EMSAs), immunohistochemistry and in vivo xenotransplantation. Aspirin significantly induced apoptosis and reduced the viability, self-renewal potential, and expression of proteins involved in inflammation and stem cell signaling. Aspirin also reduced the growth and invasion of tumors in vivo, and it significantly prolonged the survival of mice with orthotopic pancreatic xenografts in combination with gemcitabine. This was associated with a decreased expression of markers for progression, inflammation and desmoplasia. These findings were confirmed in tissue samples obtained from patients who had or had not taken aspirin before surgery. Importantly, aspirin sensitized cells that were resistant to gemcitabine and thereby enhanced the therapeutic efficacy. Aspirin showed no obvious toxic effects on normal cells, chick embryos or mice. These results highlight aspirin as an effective, inexpensive and well-tolerated co-treatment to target inflammation, desmoplasia and CSC features PDA. Impact Journals LLC 2015-02-05 /pmc/articles/PMC4496413/ /pubmed/25846752 Text en Copyright: © 2015 Zhang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhang, Yiyao
Liu, Li
Fan, Pei
Bauer, Nathalie
Gladkich, Jury
Ryschich, Eduard
Bazhin, Alexandr V.
Giese, Nathalia A.
Strobel, Oliver
Hackert, Thilo
Hinz, Ulf
Gross, Wolfgang
Fortunato, Franco
Herr, Ingrid
Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
title Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
title_full Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
title_fullStr Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
title_full_unstemmed Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
title_short Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
title_sort aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496413/
https://www.ncbi.nlm.nih.gov/pubmed/25846752
work_keys_str_mv AT zhangyiyao aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT liuli aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT fanpei aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT bauernathalie aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT gladkichjury aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT ryschicheduard aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT bazhinalexandrv aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT giesenathaliaa aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT strobeloliver aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT hackertthilo aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT hinzulf aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT grosswolfgang aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT fortunatofranco aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer
AT herringrid aspirincounteractscancerstemcellfeaturesdesmoplasiaandgemcitabineresistanceinpancreaticcancer